Patent 8999941 was granted and assigned to ScinoPharm Taiwan on April, 2015 by the United States Patent and Trademark Office.
The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.